Elliott M. Antman

TL;DR: Patients with LBW in ENGAGE AF-TIMI 48 had in general a more fragile clinical status and poorer international normalized ratio control, resulting in similar efficacy compared with warfarin, while major or clinically relevant non-MB and net outcomes were most favorable with edoxaban as compared to warFarin in LBW patients.

TL;DR: The cycle of research begins with identification of an idea, design of the study to answer the scientific question that is posed, conducting and analyzing the findings, and publishing the results.

TL;DR: In a subgroup analysis, a reperfusion strategy including enoxaparin significantly improved outcomes compared with UFH among high-risk STEMI patients with DM undergoing fibrinolysis.

TL;DR: The bivalirudin story has not ended because of a new sponsor and a second look under-taken by several groups of investigators, but there was a trend toward a reduction in favor of the drug and a decision to terminate further clinical studies with bivalIRudin.

TL;DR: A subgroup meta-analysis from the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events and the Thrombolysis in Myocardial Infarction studies has shown that enoxAParin is superior to unfractionated heparin in reducing the composite end points of death, myocardial infarction, and emergency revascularization in patients with Q-wave myocardia.